ADMA Biologics Shareholders Face August Deadline in Fraud Suit

The core of the legal complaint centers on allegations that ADMA Biologics masked its true financial health through deceptive practices. Plaintiffs claim the company engaged in undisclosed related party transactions and utilized channel stuffing to artificially inflate revenue figures. These actions, according to the lawsuit, suggest a failure of internal controls that left investors relying on materially misleading statements about the company's operational viability.

Those seeking to participate in the suit are not required to take immediate action to remain part of the class, though they may choose to retain independent counsel. Howard G. Smith is coordinating inquiries for affected shareholders through his Bensalem, Pennsylvania office. The litigation highlights a period of volatility for ADMA, specifically focusing on the discrepancy between the company’s public positive projections and the internal realities of its business dealings during the specified nineteen-month window.